CA2438515A1 - Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih - Google Patents

Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih Download PDF

Info

Publication number
CA2438515A1
CA2438515A1 CA002438515A CA2438515A CA2438515A1 CA 2438515 A1 CA2438515 A1 CA 2438515A1 CA 002438515 A CA002438515 A CA 002438515A CA 2438515 A CA2438515 A CA 2438515A CA 2438515 A1 CA2438515 A1 CA 2438515A1
Authority
CA
Canada
Prior art keywords
hiv
peptide
coreceptor
binding
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438515A
Other languages
English (en)
Inventor
Oleg Chertov
Joost J. Oppenheim
Xin Chen
Connor Mcgrath
Raymond C. Ii. Sowder
Jacek Lubkowski
Michele Wetzel
Thomas J. Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
US Government
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438515A1 publication Critical patent/CA2438515A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouvelles techniques et de nouvelles compositions permettant d'inhiber les interactions entre des virus de l'immunodéficience humaine (VIH) et des corécepteurs viraux, notamment les corécepteurs de CXCR4 et/ou de CCR5. L'agent de liaison anti-corécepteur comprend une nouvelle partie peptidique de protéine d'enveloppe gp120 du VIH-1, ainsi que des analogues de peptide et des mimétiques de ce peptide, qui se lie spécifiquement à ce ou ces corécepteurs, ou qui module l'activité de ces derniers. Cet agent de liaison anti-corécepteur convient pour un traitement prophylactique ou thérapeutique destiné à empêcher ou à inhiber la liaison du VIH à une cellule sensible et il réduit ainsi l'infection et/ou atténue ou traite des maladies liées. Dans un autre mode de réalisation de l'invention, les peptides, les analogues et les mimétiques sont efficaces pour inhiber des corécepteurs directs de liaison par le virus HIV, des corécepteurs de liaison par des peptides ou des protéines gp 120 du VIH, la fusion du VIH avec des cellules hôtes cible, l'entrée d'une protéine VIF du VIH dans des cellules hôtes, la réplication du VIH et la transmission du VIH entre des cellules et des hôtes. Dans des modes de réalisation de l'invention plus détaillés, les agents de liaison anti-récepteur de l'invention sont multi-tropiques et présentent une activité contre les interactions du VIH avec de multiples corécepteurs CXCR4 et CCR5.
CA002438515A 2001-02-15 2002-02-15 Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih Abandoned CA2438515A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26953401P 2001-02-15 2001-02-15
US60/269,534 2001-02-15
PCT/US2002/005063 WO2002064154A2 (fr) 2001-02-15 2002-02-15 Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih

Publications (1)

Publication Number Publication Date
CA2438515A1 true CA2438515A1 (fr) 2002-08-22

Family

ID=23027674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438515A Abandoned CA2438515A1 (fr) 2001-02-15 2002-02-15 Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih

Country Status (4)

Country Link
US (1) US20060116325A1 (fr)
EP (1) EP1361886A2 (fr)
CA (1) CA2438515A1 (fr)
WO (1) WO2002064154A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055041A2 (fr) 2002-12-13 2004-07-01 Case Western Reserve University Agents inducteurs de defensine et procedes correspondants
US7442375B2 (en) 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
US20040224883A1 (en) * 2002-12-13 2004-11-11 Case Western Reserve University Compositions and methods for treating HIV infections
WO2005056581A2 (fr) * 2003-12-10 2005-06-23 Universite De Lausanne Peptide susceptible de se lier specifiquement a un recepteur de chimiokine et son utilisation
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
JP6023928B2 (ja) * 2011-08-15 2016-11-09 国立大学法人 熊本大学 分子擬態粘膜エイズワクチン

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612132A (en) * 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5807979A (en) * 1988-04-08 1998-09-15 The Scripps Research Institute Synthetic, three-dimensionally stabilized polypeptide mimics of HIV
US6080846A (en) * 1989-08-18 2000-06-27 Institut Pasteur Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus
US5876724A (en) * 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
WO1994013804A1 (fr) * 1992-12-04 1994-06-23 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
US5691135A (en) * 1993-01-26 1997-11-25 The Regents Of The University Of California Immunoglobulin superantigen binding to gp 120 from HIV
WO1994018221A1 (fr) * 1993-02-02 1994-08-18 The Scripps Research Institute Procedes de production de sites de liaison de polypeptides
US5614559A (en) * 1993-11-23 1997-03-25 Procept Inc. Compound for inhibiting HIV infectivity
US5689914A (en) * 1994-06-15 1997-11-25 Zenco (No. 4) Limited Method of hybrid crop production using dehydrated pollen from storage
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US5928881A (en) * 1996-07-11 1999-07-27 Smithkline Beecham Corporation Method of identifying agonists and antagonist for CC-CKR5 receptor
US5798206A (en) * 1997-01-10 1998-08-25 New York Blood Center Methods for screening of test compounds for inhibiting binding of a CD4-HIV 1 complex to a chemokine receptor
DE19854845B4 (de) * 1998-01-30 2011-02-24 Heidelberger Druckmaschinen Ag Verfahren und Vorrichtung zur automatischen Erfassung von mindestens einer Druckplattenkante
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders

Also Published As

Publication number Publication date
US20060116325A1 (en) 2006-06-01
EP1361886A2 (fr) 2003-11-19
WO2002064154A2 (fr) 2002-08-22
WO2002064154A3 (fr) 2003-04-24

Similar Documents

Publication Publication Date Title
JP7227951B2 (ja) 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン
EP3390441B1 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
JP2023542417A (ja) Ｋｒａｓ変異に特異的ｔ細胞受容体のスクリーニング及び抗腫瘍用途
KR20230028453A (ko) 치료 용도를 위한 ccr8 항체
JP4712975B2 (ja) 炎症反応を阻害又は増強するための組成物及び方法
CN116063464A (zh) 冠状病毒的抗体或其抗原结合片段
JP2014209914A (ja) Ｃｘｃケモカイン受容体４（ｃｘｃｒ４）拮抗性ポリペプチド
JPH10511557A (ja) 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法
CN115315435A (zh) IL-7Rαγc结合化合物
JP2022553817A (ja) ＩＬ－２ＲβγＣ結合化合物
US20090285815A1 (en) Immunoconjugates comprising cd4 and immunoglobin molecules for the treatment of hiv infection
JP2020501506A (ja) 抗ＮＫｐ４６抗体およびその治療的使用
JPH04500970A (ja) マクロファージ由来炎症メディエーター　（ｍｉｐ―２）
KR20030009450A (ko) 트롬보포이에틴 수용체 조절성 펩티드
EP3286212B1 (fr) Polypeptides ciblant une fusion du vih
JP2023505169A (ja) Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
AU615940B2 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
US20110263485A1 (en) Bifunctional Griffithsin Analogs
US20230390360A1 (en) Methods of using interleukin-2 agents
RU2337922C2 (ru) ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП
US20060116325A1 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
EP1161455A1 (fr) Nouvelle proteine chimere permettant de prevenir et de traiter l'infection due au vih
US20020064770A1 (en) Binding compounds and methods for identifying binding compounds
AU2002253984A1 (en) Methods and compositions for inhibiting HIV-coreceptor interactions
CN117430716B (zh) 靶向保守的HIV gp41亚基近膜端外区的重组干扰素药物及其应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued